5-Amino-1MQ

5-amino 1MQ · 5-Amino-1-methylquinolinium

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that blocks the enzyme responsible for converting nicotinamide to N-methylnicotinamide, potentially enhancing cellular energy production and promoting fat loss.

AOD-9604

Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) with a tyrosine residue added for enhanced stability. It stimulates lipolysis and inhibits lipogenesis without affecting blood glucose or IGF-1, and has been granted FDA GRAS status as a food ingredient.

AOD-9604 Oral

Anti-Obesity Drug 9604 · Fragment 177-191

AOD-9604 Oral is a synthetic peptide fragment derived from human growth hormone that specifically targets fat metabolism without affecting blood sugar levels. This oral formulation offers improved convenience compared to injectable versions while maintaining the peptide's ability to stimulate lipolysis and reduce fat accumulation.

Adipotide

CKGGRAKDC-GG-D(KLAKLAK)2 · Prohibitin Targeting Peptide

Adipotide is an experimental peptide compound designed to selectively target and destroy blood vessels that supply white adipose tissue. This mechanism causes fat cell death by cutting off their blood supply, leading to rapid fat loss in research models.

CagriSema

Cagrilintide + Semaglutide · Dual GLP-1/Amylin Agonist

CagriSema combines cagrilintide (an amylin analog) with semaglutide (a GLP-1 receptor agonist) to create a dual-action weight loss compound that targets multiple metabolic pathways.

Dulaglutide

Trulicity

Dulaglutide is a long-acting GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to regulate blood glucose levels and promote weight loss. This once-weekly injectable medication works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying.

Exenatide

Byetta · Bydureon

Exenatide is a synthetic GLP-1 receptor agonist derived from Gila monster saliva that regulates blood glucose and promotes weight loss through enhanced insulin secretion and delayed gastric emptying.

FTPP

Fat Targeted Proapoptotic Peptide · Adipose-targeting peptide

FTPP (Fat Targeted Proapoptotic Peptide) is an experimental peptide designed to selectively target adipose tissue and induce fat cell death through apoptosis. This targeted approach aims to reduce fat deposits without affecting other tissues.

GLP-1 (7-37)

Glucagon-Like Peptide-1 · Native GLP-1

GLP-1 (7-37) is the biologically active form of the endogenous incretin hormone glucagon-like peptide-1. It is the natural peptide that semaglutide, tirzepatide, and other GLP-1 receptor agonists are designed to mimic, playing a central role in glucose homeostasis, appetite regulation, and metabolic function.

HGH Fragment 176-191

HGH Frag · AOD-9604 precursor

HGH Fragment 176-191 is a modified segment of the growth hormone molecule (amino acids 176-191) that retains the fat-burning properties of GH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis selectively.

Liraglutide

Saxenda · Victoza

Liraglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes treatment that demonstrates significant weight loss effects through appetite suppression and delayed gastric emptying.

Orforglipron

LY3502970

Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly that demonstrates significant weight loss and glycemic control effects in clinical trials. This non-peptide small molecule offers the benefits of traditional GLP-1 therapies without requiring injection.

Pemvidutide

ALT-801

Pemvidutide is a dual GLP-1 and glucagon receptor agonist designed to promote weight loss and improve metabolic parameters through enhanced insulin sensitivity and appetite suppression.

Retatrutide

LY3437943 · GGG Triple Agonist

Retatrutide is an investigational triple hormone receptor agonist (GIP/GLP-1/glucagon) developed by Eli Lilly. In Phase II trials, it achieved up to 24.2% body weight reduction at 48 weeks; the highest weight loss reported for any single pharmacological agent in clinical trials.

Semaglutide

Ozempic · Wegovy

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It has gained widespread attention for its significant effects on weight loss, with clinical trials demonstrating average body weight reductions of 15-17%; making it one of the most effective pharmacological weight management agents studied.

Survodutide

BI 456906

Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim that targets both metabolic pathways simultaneously for enhanced weight loss and glycemic control. This injectable peptide shows superior efficacy compared to single-receptor agonists in clinical trials for obesity and type 2 diabetes management.

Setmelanotide

Imcivree · RM-493

Setmelanotide is an FDA-approved melanocortin-4 receptor (MC4R) agonist specifically designed to treat rare genetic forms of obesity. This synthetic peptide targets specific genetic mutations that disrupt normal appetite regulation and energy balance.

Tirzepatide

Mounjaro · Zepbound

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it has demonstrated unusual weight loss of up to 22.5% in clinical trials.

Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of dopamine, norepinephrine, and serotonin. Originally developed as an anti-obesity medication, it demonstrates significant weight loss effects and potential cognitive enhancement properties.